|
|
 About Us
Milestones
2023
- The total paid-in capital was increased to 448 million NTD After the eighth round of cash capital increase.
- Received Australia Bellberry Human Research Ethics Committee and TGA approval of Phase I/II clinical trials of APC201.
- The company has been listed on the Emerging Stock Board (ESB) of the Taipei Exchange on January 12, 2023.
2022
- The company has been approved for public issuance of shares and the stock symbol is「6917」
- The total paid-in capital was increased to 348 million NTD After the seventh round of cash capital increase.
- APC201 sent to Australia and Taiwan for planned to enter Phase I/II clinical trials.
- The total paid-in capital was increased to 284 million NTD After the sixth round of cash capital increase.
2021
- LALP cream officially entered the hospital system for sales.
- Andros Pharmaceuticals passed TFDA follow-up inspection of PICS/GMP.
2020
- "Development of Topical New Dosage Form of Local Anesthetic Complex" project has received R&D subsidies from the Ministry of Economic Affairs.
- Signed a licensing cooperation contract with Hong Kong Pharmaceuticals to develop the local anesthetics market in China.
- Lead asset APC101 completed the phase 2 clinical trial report in Australia. The next phase of clinical trials can be continued.
2019
- Finished phase 2 clinical study of APC101.
2018
- President Ae-June Wang received the Excellence in Management Award at the 7th Woman Elite Entrepreneurs Competition.
- Start of phase 2 clinical study of APC101.
- Received Taiwan FDA licenses for 2% and 5% iMinos Solution.
- The PIC/s GMP facility passed TFDA audit inspection of GMP and GDP.
2017
- Established subsidiary Andros Pharmaceuticals Pty Ltd in Australia
- Received Taiwan FDA license for LALP Cream (site change).
2016
- Received Innovative Product Award from Hsinchu Science Park for “Liposomal DNA Repairing Enzyme.”
- Received Small Business Innovation Research (SBIR) Award for the development of “topical anesthetic new dosage form” project.
- PIC/s GMP certified for solution production.
2015
- PIC/s GMP certified for cream/gel production, certificate no. (AP)0445117.
- Start of phase 1 clinical study of APC101.
- Received USFDA approval of Phase 1 clinical study of APC101.
- The total paid-in capital was increased to 243 million NTD after the fifth round of cash capital increase.
- The total paid-in capital was increased to 213 million NTD after the fourth round of cash capital increase.
2014
- Approval of capital funded SBIR project by Ministry of Economic Affairs with total budget of 9.65 million NTD.
- Approval of capital funded project by Taipei City Government with total budget of 5.45 million NTD.
2013
- Approved by MOEA according to the "Biotech and New Pharmaceutical Development Act" as a Biotechnical and New Pharmaceuticals Company.
- The total paid-in capital was increased to 150 million NTD after the third round of cash capital increase.
- Approval of capital funded project by Taipei City Government with total budget of 4.7 million NTD.
- Relocated to Hsinchu Biomedical Science Park.
2012
- Established branch office at Hsinchu Biomedical Science Park.
- The total paid-in capital was increased to 100 million NTD after the second round of cash capital increase.
2011
- Received 12 million NTD of Small Business Innovation Research (SBIR) grant from Ministry of Economic Affairs (MOEA) for the development of “topical anesthetic new dosage form” project.
2010
- Approved by the Ministry of Science and Technology (MOST) for the relocation to Hsinchu Biomedical Science Park (HBSP).
- The total paid-in capital was increased to 55 million NTD after the first round of cash capital increase.
2009
- Exclusive technology transfer of "non-viral gene carrier technology" and 11 related patents from ITRI.
2008
- Established office and laboratory in ITRI incubation center.
- Andros Pharmaceuticals was established with a capital of 30 million NTD.
|
